Unlocking Digestive Health: The Tegoprazan Intermediate Advantage
Discover the essential R-5, 7-Difluorobenzo Dihydropyran-4-Ol, a key to advanced P-CAB development.
Get a Quote & SampleProduct Core Value
(R)-5,7-Difluorochroman-4-ol
This high-purity pharmaceutical intermediate is vital for the synthesis of Tegoprazan, a cutting-edge potassium-competitive acid blocker (P-CAB) designed to effectively manage acid-related gastrointestinal disorders. Its reliable quality ensures the integrity of the final Active Pharmaceutical Ingredient (API).
- Leveraging this key intermediate supports the complex Tegoprazan manufacturing process, ensuring efficient API production.
- Explore the synthesis of Tegoprazan Intermediate R-5, 7-Difluorobenzo Dihydropyran-4-Ol for novel drug development.
- Understand the crucial role of CAS 1270294-05-7 in the advanced P-CAB drug development pipeline.
- Utilize this essential component for the development of treatments for acid-related gastrointestinal disorders.
Key Product Advantages
Enhanced Synthesis Efficiency
The availability of (R)-5,7-Difluorochroman-4-ol streamlines the Tegoprazan manufacturing process, contributing to cost-effectiveness and faster production cycles for your P-CAB projects.
Guaranteed Purity and Quality
With stringent quality control, this pharmaceutical intermediate ensures high purity, which is paramount for the safety and efficacy of the final Tegoprazan API, aligning with 'Tegoprazan Intermediate R-5, 7-Difluorobenzo Dihydropyran-4-Ol' standards.
Supports Innovative Drug Development
As a critical building block, it empowers researchers and manufacturers to advance the development of novel treatments for gastrointestinal conditions, making it a cornerstone for 'Acid-related gastrointestinal disorder treatment' breakthroughs.
Key Applications
Pharmaceutical Synthesis
Essential for the precise synthesis of Tegoprazan, a vital component in the 'Tegoprazan manufacturing process' for novel pharmaceuticals.
P-CAB Drug Development
Facilitates the creation of advanced Potassium-Competitive Acid Blockers (P-CABs), addressing unmet needs in treating gastric acid-related issues.
Active Pharmaceutical Ingredient (API) Production
The reliable quality of CAS 1270294-05-7 directly impacts the production of high-grade Tegoprazan API.
Gastrointestinal Disorder Research
Supports scientific inquiry into new therapeutic strategies for conditions like GERD and peptic ulcers through the 'Tegoprazan Intermediate R-5, 7-Difluorobenzo Dihydropyran-4-Ol' component.